By employing precision diagnostic methods such as gene sequencing to identify the key underlying causes, we can administer targeted medications and tailor unique treatment plans for each patient. Precision medicine represents a crucial direction for future research and development, holding the promise of breakthroughs in the treatment of challenging diseases such as tumors and cancer.

Recently, Beijing Northland Biotechnology Co., Ltd., recommended by the Zhongguancun Administrative Committee, was interviewed by the News Channel of Beijing Television as a representative enterprise in the field of precision medicine. Nie Liya, Executive Deputy General Manager of the company, provided a detailed explanation of the concept, current development status, and future prospects of precision medicine, and highlighted the company’s recombinant human hepatocyte naked plasmid injection project. This product, through precise diagnosis and targeted drug delivery, can accurately regenerate blood vessels in ischemic areas of patients, thereby achieving therapeutic effects. Currently, this product has completed Phase II clinical trials in China.

News link: http://www.letv.com/ptv/vplay/23238933.html